Most common treatment-related adverse events (TRAEs) were anemia (83%), neutropenia (83%), leukopenia (83%), thrombocytopenia (58%), ALT increase (50%), lymphopenia (50%), and nausea (50%). This evidence concerns the gene GPT and neutropenia.